Theta Burst Stimulation for Gambling Disorder
Rolling Deep With Gambling Disorder: From Building up of Scales, Biomarkers to Therapeutic Innovation
Taipei City Hospital
75 participants
Apr 17, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to investigate the efficacy of theta burst stimulation in individuals with gambling disorder. The main goal is to compare the severity of gambling problems following 2 weeks of intervention between active group and sham group. Participants will be randomized into active and sham group. The severity of gambling problems are assessed by self-reported questionaires.
Eligibility
Inclusion Criteria2
- age between 18 and 65 years;
- fulfilling at least 4 of the Diagnostic and Statistical Manual version 5 (DSM-5) criteria of gambling disorder for at least 12-month assessed by the Structured Clinical Interview
Exclusion Criteria9
- Inability to provide informed consent or comprehend the study procedure;
- A major psychiatric illness that required chronic psychotropic medication or inpatient treatment, including schizophrenia spectrum disorder, bipolar spectrum disorder, and major depressive disorder with psychotic features.
- A current DSM-5 diagnosis of substance use disorder except nicotine use disorder or the use of one to two low-potency benzodiazepine tablets for sleep impairment;
- Have known preexisting noise-induced hearing loss, concurrent treatment with ototoxic medications, or with cochlear implants.
- Unstable medical illness, including malignancy, uncontrolled diabetes mellitus, unstable cardiac disease or recent myocardial infarction, or cerebrovascular or cardiovascular risk factors that require intensive medical management
- On medications known to lower seizure threshold (e.g., TCA, bupropion, clozapine)
- Implants controlled by physiological signals, including pacemaker, implantable cardioverter defibrillator, cochlear implant.
- Metallic objects in the head, including stenting, suture.
- Elevated risk of seizure due to traumatic brain history, seizure history, and head trauma, intracranial lesion, and alcohol or benzodiazepines withdrawal syndrome, stimulant intoxication.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Magstim Rapid 2 Plus stimulator (Magstim Co., Ltd., Whitland, United Kingdom)
sham stimulation
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05872750